<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02866799</url>
  </required_header>
  <id_info>
    <org_study_id>PI: 15/00572,15/00276,15/00996</org_study_id>
    <nct_id>NCT02866799</nct_id>
  </id_info>
  <brief_title>Multi-PAP RCT: Improving Prescription in Primary Care Patients With Multimorbidity and Polypharmacy</brief_title>
  <acronym>Multi-PAP</acronym>
  <official_title>Effectiveness of an Intervention for Improving Drug Prescription in Primary Care Patients With Multimorbidity and Polypharmacy: Study Protocol of a Cluster Randomized Clinical Trial (Multi-PAP Project)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Aragones de Ciencias de la Salud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gerencia de Atención Primaria, Madrid</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aragon Institute for Health Research (IIS Aragón)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Andaluz Health Service</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Red de Investigación en Servicios de Salud y Enfermedades Crónicas (REDISSEC)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto de Salud Carlos III</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto Aragones de Ciencias de la Salud</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study assesses the effectiveness of a complex intervention in young-old patients with
      multimorbidity and polypharmacy aimed at improving physician drug prescription in primary
      care, measured by means of the Medication Appropriateness Index (MAI)-score at six 6 (T1) and
      12 (T2) months from baseline compared to usual care.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Design: Pragmatic cluster randomized clinical trial with 12 months follow-up.

      Unit of randomization: general practitioner.

      Unit of analysis: patient.

      Setting: Primary Health Care Centres in three different Spanish Autonomous Communities
      (Aragón, Madrid and Andalucía).

      Population: Patients 65-74 years of age with multimorbidity (3 or more chronic diseases) and
      polypharmacy (5 or more drugs taken for at least three months). N=400 patients (200 in each
      arm, 5 patients per physician) will be recruited by general practitioners before
      randomization.

      Intervention: complex intervention.

      Control group: usual care.

      Variables: MAI, health care utilization, quality of life (Euroqol 5D-5L), drug therapy and
      adherence (Morisky-Green, Haynes-Sackett), clinical and socio-demographic factors. Economic
      appraisal variables: time spent training FPs, cost of teaching staff, time spent on
      physician-patient interviews, utilities measured using the EuroQol 5D-5L.

      Analysis: All analyses will be carried out adhering to the intention-to-treat principle.
      Description of baseline characteristics. Basal comparison between groups. Analysis of main
      and secondary effectiveness (between-group difference in T1-T0 MAI score, with corresponding
      CI95%); multilevel analysis will be used to adjust models. Estimated quality-adjusted life
      years (QALYs) gained at the population level. Calculation of cost-utility ratio.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Actual">February 2018</completion_date>
  <primary_completion_date type="Actual">February 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Medication Appropriateness Index (MAI) score</measure>
    <time_frame>Change from baseline MAI score at 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Medication Appropriateness Index (MAI) score</measure>
    <time_frame>Change from baseline MAI score at 12 months</time_frame>
    <description>Quality of Life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morisky-Green questionnaire</measure>
    <time_frame>Baseline, at six 6 months and at 12 months</time_frame>
    <description>Therapeutic adherence questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haynes-Sackett test</measure>
    <time_frame>Baseline, at six 6 months and at 12 months</time_frame>
    <description>Therapeutic adherence test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Euroqol 5D-5L questionnaire</measure>
    <time_frame>Baseline, at six 6 months and at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of health services</measure>
    <time_frame>at six 6 months and at 12 months</time_frame>
    <description>Unscheduled and/or avoidable hospitalizations, use of emergency services and primary care (FP and nurse).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication safety</measure>
    <time_frame>at six 6 months and at 12 months</time_frame>
    <description>measured as the incidence of adverse drug reactions and potentially hazardous interactions, classified using the taxonomy proposed by Otero-López</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient perception of shared decision-making</measure>
    <time_frame>Baseline and at six 6 months and at 12 months</time_frame>
    <description>measured using a single, multiple choice question, formulated ad hoc.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">593</enrollment>
  <condition>Multimorbidity</condition>
  <condition>Polypharmacy</condition>
  <condition>Other Diagnoses, Comorbidities, and Complications</condition>
  <arm_group>
    <arm_group_label>Multi-PAP intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Complex intervention with general practitioners and patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive the usual clinical care</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Multi-PAP</intervention_name>
    <description>Complex intervention based on the ARIADNE principles with two main components: 1) Training of general practitioners and 2) Patient centered clinical interview.</description>
    <arm_group_label>Multi-PAP intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual care</intervention_name>
    <description>Patients will receive the usual clinical care based on current clinical practice guidelines.</description>
    <arm_group_label>Multi-PAP intervention</arm_group_label>
    <arm_group_label>Usual care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients 65-74 years of age with multimorbidity (3 or more chronic diseases) and
             polypharmacy (5 or more drugs taken for at least three months).

          -  Informed consent.

        Exclusion Criteria:

          -  Institutionalized patient at nursing homes or similar

          -  Life expectancy &lt; 12 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandra Prados-Torres, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Aragonés de Ciencias de la Salud (IACS)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel Prados-Torres, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Servicio Andaluz de Salud (Andaluz Health Service)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Isabel Del Cura-González, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gerencia de Atención Primaria, Madrid</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Málaga</city>
        <state>Andalucía</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zaragoza</city>
        <state>Aragón</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Prados-Torres A, Del Cura-González I, Prados-Torres JD, Leiva-Fernández F, López-Rodríguez JA, Calderón-Larrañaga A, Muth C. [Multimorbidity in general practice and the Ariadne principles. A person-centred approach]. Aten Primaria. 2017 May;49(5):300-307. doi: 10.1016/j.aprim.2016.11.013. Epub 2017 Apr 17. Spanish.</citation>
    <PMID>28427915</PMID>
  </reference>
  <reference>
    <citation>Prados-Torres D, Del Cura-González I, Prados-Torres A. [Towards a multimorbidity care model in Primary Care]. Aten Primaria. 2017 May;49(5):261-262. doi: 10.1016/j.aprim.2016.11.004. Epub 2017 Jan 11. Spanish.</citation>
    <PMID>28089227</PMID>
  </reference>
  <results_reference>
    <citation>Prados-Torres A, Del Cura-González I, Prados-Torres D, López-Rodríguez JA, Leiva-Fernández F, Calderón-Larrañaga A, López-Verde F, Gimeno-Feliu LA, Escortell-Mayor E, Pico-Soler V, Sanz-Cuesta T, Bujalance-Zafra MJ, Morey-Montalvo M, Boxó-Cifuentes JR, Poblador-Plou B, Fernández-Arquero JM, González-Rubio F, Ramiro-González MD, Coscollar-Santaliestra C, Martín-Fernández J, Barnestein-Fonseca MP, Valderas-Martínez JM, Marengoni A, Muth C; Multi-PAP Group. Effectiveness of an intervention for improving drug prescription in primary care patients with multimorbidity and polypharmacy: study protocol of a cluster randomized clinical trial (Multi-PAP project). Implement Sci. 2017 Apr 27;12(1):54. doi: 10.1186/s13012-017-0584-x.</citation>
    <PMID>28449721</PMID>
  </results_reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2016</study_first_submitted>
  <study_first_submitted_qc>August 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2016</study_first_posted>
  <last_update_submitted>February 5, 2018</last_update_submitted>
  <last_update_submitted_qc>February 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Aragones de Ciencias de la Salud</investigator_affiliation>
    <investigator_full_name>Alexandra Prados Torres</investigator_full_name>
    <investigator_title>Medical Doctor, PhD</investigator_title>
  </responsible_party>
  <keyword>Multimorbidity</keyword>
  <keyword>Primary Health Care</keyword>
  <keyword>Polypharmacy</keyword>
  <keyword>Comorbidity</keyword>
  <keyword>Medication Adherence</keyword>
  <keyword>Medication Appropriateness Index</keyword>
  <keyword>Patient-Centered Care</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

